Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?

Affiliations

¹ Solid Tumor Oncology Service, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 1021, USA. Electronic address: mas9913@med.cornell.edu.

Comment

Manish A Shah. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):1433-1434.

doi: 10.1016/S1470-2045(17)30720-9. Epub 2017 Oct 13.

¹ Solid Tumor Oncology Service, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 1021, USA. Electronic address: mas9913@med.cornell.edu.

No abstract available

Comment on

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K. Doi T, et al. Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13. Lancet Oncol. 2017. PMID: 29037983 Clinical Trial.